Clinica Cayanga Medical Resources


Clinical Updates


Clinical Updates
Alzheimer's Disease
Arthritis
Benign Prostatic Hypertrophy
Chronic Lymphocytic Leukemia
Depression
Diabetes Mellitus
Dyspepsia
Erectile Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Prostate Cancer
Stroke
Tinnitus
 
Medical Library
Breaking Medical News
Clinical Tools
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
Free Medical Journal
History Taking and Physical Examination
Medical Journal (popular)
Medical Organizations
Palm Tools
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator
 
 

 

LDL Cholesterol "The lower the better" in patient with acute and chronic cardiovascular disease

 

Clinical Question:
Are there evidence that statin is effective in reducing death on patient with acute and chronic cardiovascular disease?

Bottom Line:

For patients at high risk of coronary artery disease there is growing evidence for the concept of 'the lower, the better' regarding LDL cholesterol levels. The target values for LDL cholesterol of less than 1.8 mmol/l (<70 mg/dl) should be considered for all patients with coronary artery disease or equivalent coronary risk.Ongoing trials are further investigating the safety of lower target values in patients at various risk of coronary artery disease.

Reference:
Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses.Briel M, Nordmann AJ, Bucher HC. Curr Opin Lipidol. 2005 Dec;16(6):601-5.

Study Design:
Metaanalysis (Randomized Controlled Trials)

Synopsis:
The author summarized evidence from recent clinical trials and metaanalyses on the efficacy of statin therapy to reduce death, myocardial infarction and stroke, and to review the effects of statins in patients with low LDL cholesterol, diabetes, end-stage renal disease, and acute coronary syndrome. In large metaanalyses of randomized controlled trials relative risk reductions from statins compared with placebo for patients with manifest or with risk factors for coronary artery disease were 13% for overall mortality, 26% for fatal and nonfatal myocardial infarction, and 18% for fatal and nonfatal stroke. Evidence from large trials suggests that patients with type II diabetes compared with patients without diabetes have similar risk reductions from statins for cardiovascular events, but this benefit is not seen in patients with diabetes and end-stage renal disease. In patients with acute coronary syndrome, early treatment with high-dose atorvastatin reduces cardiovascular morbidity after the first 4 months following the event, but the impact on mortality endpoints remains less clear. Results from recent trials in patients with stable coronary artery disease or type II diabetes suggest that statins provide benefit at considerable low LDL cholesterol levels. Therefore, target values for LDL cholesterol of less than 1.8 mmol/l (<70 mg/dl) should be considered for all patients with coronary artery disease or equivalent coronary risk.

 

 

   

Home | Introduction | Scheduling a Visit| Laboratory Work Reaching Us | Map to our Office | About the Doctors

 

 

 ©2005 Clinica Cayanga. All rights reserved.